Current Report Filing (8-k)
January 13 2020 - 04:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 13, 2020
RIGEL
PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
0-29889
|
|
94-3248524
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
1180 Veterans Boulevard
South San Francisco, CA
(Address of principal executive offices)
94080
(Zip Code)
Registrant’s telephone number, including
area code: (650) 624-1100
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities pursuant to Section 12 (b) of the Act:
Title of Each Class
|
|
Trading Symbol(s)
|
|
Name of Each Exchange on Which
Registered
|
Common Stock, par value $0.001 per share
|
|
RIGL
|
|
The Nasdaq Stock Market LLC
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On January 13, 2020, Rigel Pharmaceuticals, Inc.
issued a press release titled “Rigel Pharmaceuticals Provides Business Update,” a copy of which is furnished pursuant
to Item 2.02 as Exhibit 99.1 hereto.
Item 9.01.
|
Financial Statements and Exhibits.
|
The information in this report, including the exhibit hereto,
shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The
information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S.
Securities and Exchange Commission made by us, whether made before or after the date hereof, regardless of any general incorporation
language in such filing.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereto duly authorized.
Dated: January
13, 2020
|
RIGEL PHARMACEUTICALS, INC.
|
|
|
By:
|
/s/ Dolly A. Vance
|
|
|
Dolly A. Vance
|
|
|
Executive Vice President, General Counsel and Corporate Secretary
|
Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
From Mar 2023 to Mar 2024